CD22 and acute lymphoblastic leukemia: In the context of ALL, several new therapies, including bispecific T-cell engager blinatumomab, anti-CD22 antibody inotuzumab ozogomycin and CAR-therapy Tisagenlecleucel have been introduced and got FDA approvement.